These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 17699280

  • 21. [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
    Kumagai H, Sakata K, Matsuura T, Imai M, Onami T, Iigaya K, Saruta T.
    Nihon Rinsho; 2002 Oct; 60(10):2005-13. PubMed ID: 12397699
    [Abstract] [Full Text] [Related]

  • 22. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E, Scateni S, Di Maio V, Versacci P, Masciangelo R, Romero S.
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [Abstract] [Full Text] [Related]

  • 23. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [Abstract] [Full Text] [Related]

  • 24. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M, Høj Nielsen A, Strandgaard S, Kamper AL.
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [Abstract] [Full Text] [Related]

  • 25. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R.
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [Abstract] [Full Text] [Related]

  • 26. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 27. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
    Bilić M, Munjas-Samarin R, Ljubanović D, Horvatić I, Galesić K.
    Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
    [Abstract] [Full Text] [Related]

  • 28. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P, Fairley K, Packham D.
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J, Abitbol C, Montané B, Zilleruelo G.
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [Abstract] [Full Text] [Related]

  • 30. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [Abstract] [Full Text] [Related]

  • 31. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
    Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M.
    Nephrol Dial Transplant; 2004 Jul; 19(7):1716-23. PubMed ID: 15128880
    [Abstract] [Full Text] [Related]

  • 32. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 33. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun 28; 349(9069):1857-63. PubMed ID: 9217756
    [Abstract] [Full Text] [Related]

  • 34. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 35. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2003 Mar 26; 4(1):43-7. PubMed ID: 12692753
    [Abstract] [Full Text] [Related]

  • 36. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
    Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A.
    Am J Hypertens; 2007 Oct 26; 20(10):1092-6. PubMed ID: 17903693
    [Abstract] [Full Text] [Related]

  • 37. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul 26; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 38. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 26; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 39. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH, SOT-AT1 Study Group.
    Heart; 2011 Mar 26; 97(6):479-84. PubMed ID: 21296780
    [Abstract] [Full Text] [Related]

  • 40. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J, Kanno Y, Suzuki H.
    Intern Med; 2006 Mar 26; 45(4):193-8. PubMed ID: 16543688
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.